SCHEMBL1102910

SCHEMBL1102910

CC1(C)c2ccccc2N(c2c3ccccc3c(-c3cccc4ccccc34)c3ccncc23)c2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.37
MAPT P10636 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPK1 P28482 2/20 0.36
GAA P10253 1/20 0.34
SLC22A12 Q96S37 1/20 0.33
KDR P35968 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
POLB P06746 1/20 0.33
IKBKE Q14164 1/20 0.32
TBK1 Q9UHD2 1/20 0.32
DHFR P00374 1/20 0.32
BCHE P06276 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102553 0.87 LMNA (0.37) MAPTMEN1KMT2AKDM4EMAPK1
SCHEMBL1102713 0.84 TNF (0.39) TNFMAPTKDM4EMAPK1SLC22A12
SCHEMBL1102874 0.83 LMNA (0.33) TNFMAPK1GAAALDH1A1
SCHEMBL1102915 0.82 TNF (0.40) TNFMAPTKDM4EMAPK1SLC22A12
SCHEMBL1102855 0.82 TNF (0.40) TNFMAPTKDM4ESLC22A12POLB
SCHEMBL1102847 0.82 CYP17A1 (0.36) MAPTMEN1KMT2AKDM4ESLC22A12
SCHEMBL1102819 0.82 TNF (0.40) TNFMAPTKDM4EMAPK1SLC22A12
SCHEMBL1103237 0.82 MAPT (0.39) MAPTMEN1KMT2AKDM4EMAPK1
SCHEMBL1102833 0.80 TNF (0.41) TNFMAPTMEN1KMT2AKDM4E
SCHEMBL1103611 0.79 MEN1 (0.37) MAPTMEN1KMT2AKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 TNF 3803/4885MAPT 3162/4885MEN1 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.